In the decades-long war against disease, pharmaceutical companies have learned to build drugs like locksmiths—designing compounds that fit neatly into molecular pockets, disabling enzymes and receptors with surgical precision. But not every biological lock comes with a keyhole. Protein–protein interactions, or PPIs, often involve broad, flat, and shifting surfaces that refuse to conform to conventional
AusperBio Therapeutics has completed patient enrollment in its Phase III AUSHINE trial evaluating AHB‑137 for the treatment of HBeAg-negative chronic hepatitis B. The randomized, double-blind, multicenter study, launched in China under regulatory clearance from the Center for Drug Evaluation, surpassed its initial enrollment goal with over 570 patients enrolled within five months. AHB‑137 is being
Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has
Japan approves Sephience for PKU across all ages. Find out what this means for PTC Therapeutics' global rare disease expansion strategy.
Flagship Pioneering has launched a new research program with Pfizer through its portfolio company Repertoire Immune Medicines, focused on the development of T cell receptor (TCR) bispecifics for metastatic prostate cancer. This marks the eighth initiative under the broader Flagship–Pfizer strategic alliance. The program will harness Repertoire’s DECODE platform to map immune synapse interactions and
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.
France grants compassionate use access to GenSight Biologics’ LUMEVOQ for LHON. Explore what this decision changes and what risks remain.
FDA approves subcutaneous Lunsumio VELO for relapsed follicular lymphoma. Explore what this changes for bispecific antibodies and outpatient cancer care.
T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.
Find out how Jacobio Pharma’s global licensing deal with AstraZeneca could reshape KRAS‑targeted cancer therapy development.